We’ve recently updated our valuation analysis.

SOPHiA GENETICS Valuation

Is SOPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOPH?

Other financial metrics that can be useful for relative valuation.

SOPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does SOPH's PS Ratio compare to its peers?

The above table shows the PS ratio for SOPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.5x
STRM Streamline Health Solutions
4.3x18.4%US$101.7m
TRHC Tabula Rasa HealthCare
0.3x10.6%US$109.5m
OPRX OptimizeRx
5.1x17.2%US$320.8m
MTBC CareCloud
0.3x7.0%US$49.3m
SOPH SOPHiA GENETICS
2.9x26.9%US$131.0m

Price-To-Sales vs Peers: SOPH is expensive based on its Price-To-Sales Ratio (2.9x) compared to the peer average (2.5x).


Price to Earnings Ratio vs Industry

How does SOPH's PE Ratio compare vs other companies in the US Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.9%
n/an/an/a

Price-To-Sales vs Industry: SOPH is expensive based on its Price-To-Sales Ratio (2.9x) compared to the US Healthcare Services industry average (2.2x)


Price to Sales Ratio vs Fair Ratio

What is SOPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOPH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.9x
Fair PS Ratio2.7x

Price-To-Sales vs Fair Ratio: SOPH is expensive based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).


Share Price vs Fair Value

What is the Fair Price of SOPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SOPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SOPH's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SOPH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.04
US$8.67
+324.8%
54.4%US$12.00US$2.00n/a3
Dec ’23US$2.27
US$8.67
+281.8%
54.4%US$12.00US$2.00n/a3
Nov ’23US$2.21
US$12.50
+465.6%
4.0%US$13.00US$12.00n/a2
Oct ’23US$2.63
US$12.50
+375.3%
4.0%US$13.00US$12.00n/a2
Sep ’23US$3.05
US$12.50
+309.8%
4.0%US$13.00US$12.00n/a2
Aug ’23US$3.38
US$13.00
+284.6%
7.7%US$14.00US$12.00n/a2
Jul ’23US$3.73
US$13.00
+248.5%
7.7%US$14.00US$12.00n/a2
Jun ’23US$3.80
US$13.00
+242.1%
7.7%US$14.00US$12.00n/a2
May ’23US$6.43
US$17.50
+172.2%
2.9%US$18.00US$17.00n/a2
Apr ’23US$7.80
US$17.50
+124.4%
2.9%US$18.00US$17.00n/a2
Mar ’23US$11.88
US$20.50
+72.6%
12.2%US$23.00US$18.00n/a2
Feb ’23US$11.76
US$23.00
+95.6%
0%US$23.00US$23.00n/a2
Jan ’23US$14.10
US$23.00
+63.1%
0%US$23.00US$23.00n/a2
Dec ’22US$13.29
US$23.00
+73.1%
0%US$23.00US$23.00US$2.272
Nov ’22US$14.00
US$23.50
+67.9%
2.1%US$24.00US$23.00US$2.212
Oct ’22US$18.80
US$23.50
+25.0%
2.1%US$24.00US$23.00US$2.632
Sep ’22US$19.21
US$23.00
+19.7%
3.6%US$24.00US$22.00US$3.053

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies